Advantages of Conducting Clinical Trials in Bulgaria (1995–2009)

Patent Protection Policy in the Therapeutic Group of Statins

“…other aspects of studying are the patent policy of the companies or differences among the countries and their influence on the generic entries (5,16,22). A lot of studies are focused on the effect of the generic medicines entry on the pricing and reimbursement of medicines (8,23) and on the utilization of medicines after the patent expiration (2,18,19,20).…”

Budget Impact Model of New Antiretroviral Biotechnology Medicines for Treatment of HIV/AIDS Patients in Bulgaria

“…As part of the centralized european procedure all of the antiretroviral medicines are authorized for sale in Bulgaria which makes them available for the therapy of AiDS patients (lamivudine, zidovudine, abacavir, lopinavir, ritonavir, efavirenz, etc.) (1,23). Recently the newest antiretroviral drugs like tenofovir disoproxil, emtricitabine and darunavir have been authorized (28).…”